$EYEN
EYENOVIA, INC.

2023 Q3 Form 10-Q Financial Statement

#000141057823001760 Filed on August 11, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $1.198K $0.00
YoY Change
Cost Of Revenue $1.198K
YoY Change
Gross Profit $0.00
YoY Change
Gross Profit Margin 0.0%
Selling, General & Admin $2.940M $3.150M
YoY Change -12.33% -10.88%
% of Gross Profit
Research & Development $3.578M $2.811M
YoY Change -7.71% -21.63%
% of Gross Profit
Depreciation & Amortization $320.0K $124.2K
YoY Change 285.54% 76.17%
% of Gross Profit
Operating Expenses $6.520M $5.961M
YoY Change -9.82% -16.3%
Operating Profit -$6.520M -$5.961M
YoY Change -9.82% -16.3%
Interest Expense $679.2K $558.0K
YoY Change 283.44% 263.67%
% of Operating Profit
Other Income/Expense, Net -$818.5K $119.5K
YoY Change -1264.74% 257.89%
Pretax Income -$7.340M -$6.220M
YoY Change 0.42% -14.08%
Income Tax
% Of Pretax Income
Net Earnings -$7.339M -$6.216M
YoY Change 0.41% -14.13%
Net Earnings / Revenue -612582.05%
Basic Earnings Per Share -$0.18 -$0.16
Diluted Earnings Per Share -$0.18 -$0.16
COMMON SHARES
Basic Shares Outstanding 0.000 38.00M
Diluted Shares Outstanding 40.14M 38.09M

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $20.70M $17.47M
YoY Change 18.98% -18.78%
Cash & Equivalents $20.70M $17.50M
Short-Term Investments $0.00 $0.00
Other Short-Term Assets $4.880M $4.734M
YoY Change -53.91% 66.59%
Inventory $50.30K
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $26.53M $23.28M
YoY Change -9.8% -9.12%
LONG-TERM ASSETS
Property, Plant & Equipment $3.531M $3.698M
YoY Change 163.01% 162.92%
Goodwill
YoY Change
Intangibles $2.123M
YoY Change
Long-Term Investments $200.0K $198.7K
YoY Change -0.07% -1.36%
Other Assets $690.0K $258.0K
YoY Change 6.86% -97.0%
Total Long-Term Assets $8.332M $6.070M
YoY Change 319.06% -39.26%
TOTAL ASSETS
Total Short-Term Assets $26.53M $23.28M
Total Long-Term Assets $8.332M $6.070M
Total Assets $34.87M $29.35M
YoY Change 11.02% -17.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.426M $1.313M
YoY Change 29.06% -51.14%
Accrued Expenses $2.060M $1.742M
YoY Change -19.67% -1.76%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due $3.010M $947.2K
YoY Change -87.25%
Total Short-Term Liabilities $6.548M $4.064M
YoY Change -40.56% -66.08%
LONG-TERM LIABILITIES
Long-Term Debt $11.10M $13.18M
YoY Change
Other Long-Term Liabilities $1.440M $1.584M
YoY Change 2278.59% 11608.94%
Total Long-Term Liabilities $12.54M $14.76M
YoY Change 20613.58% 108996.38%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.548M $4.064M
Total Long-Term Liabilities $12.54M $14.76M
Total Liabilities $19.09M $18.82M
YoY Change 72.31% 56.94%
SHAREHOLDERS EQUITY
Retained Earnings -$137.5M -$130.2M
YoY Change 22.68% 24.22%
Common Stock $4.290K $3.817K
YoY Change 20.74% 13.5%
Preferred Stock
YoY Change
Treasury Stock (at cost) $5.221M $4.494M
YoY Change
Treasury Stock Shares
Shareholders Equity $15.78M $10.52M
YoY Change
Total Liabilities & Shareholders Equity $34.87M $29.35M
YoY Change 11.02% -17.58%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$7.339M -$6.216M
YoY Change 0.41% -14.13%
Depreciation, Depletion And Amortization $320.0K $124.2K
YoY Change 285.54% 76.17%
Cash From Operating Activities -$5.840M -$4.715M
YoY Change -14.33% 0.33%
INVESTING ACTIVITIES
Capital Expenditures $580.0K $1.201M
YoY Change -354.35% -1225.16%
Acquisitions
YoY Change
Other Investing Activities -$1.120M -$82.81K
YoY Change -1830.8% -2.81%
Cash From Investing Activities -$1.710M -$1.284M
YoY Change 947.02% 568.9%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 10.78M 5.001M
YoY Change 275.3% -1670.07%
NET CHANGE
Cash From Operating Activities -5.840M -4.715M
Cash From Investing Activities -1.710M -1.284M
Cash From Financing Activities 10.78M 5.001M
Net Change In Cash 3.230M -998.2K
YoY Change -178.63% -80.84%
FREE CASH FLOW
Cash From Operating Activities -$5.840M -$4.715M
Capital Expenditures $580.0K $1.201M
Free Cash Flow -$6.420M -$5.916M
YoY Change -2.56% 28.82%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Central Index Key
EntityCentralIndexKey
0001682639
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
38169398
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36668980
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
0
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38365
dei Entity Registrant Name
EntityRegistrantName
EYENOVIA, INC.
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-1178401
dei Entity Address Address Line1
EntityAddressAddressLine1
295 Madison Avenue, Suite 2400
dei Entity Address City Or Town
EntityAddressCityOrTown
NEW YORK
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10017
dei City Area Code
CityAreaCode
833
dei Local Phone Number
LocalPhoneNumber
393-6684
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
EYEN
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17468088
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22863520
CY2023Q2 eyen Deferred Clinical Supply Costs
DeferredClinicalSupplyCosts
3578326
CY2022Q4 eyen Deferred Clinical Supply Costs
DeferredClinicalSupplyCosts
2284931
CY2023Q2 eyen License Fee And Expense Reimbursements Receivables
LicenseFeeAndExpenseReimbursementsReceivables
429006
CY2022Q4 eyen License Fee And Expense Reimbursements Receivables
LicenseFeeAndExpenseReimbursementsReceivables
1183786
CY2022Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
119550
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1801373
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1190719
CY2023Q2 us-gaap Assets Current
AssetsCurrent
23276793
CY2022Q4 us-gaap Assets Current
AssetsCurrent
27642506
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3698421
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1295115
CY2023Q2 eyen Security Deposits
SecurityDeposits
198674
CY2022Q4 eyen Security Deposits
SecurityDeposits
80874
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1915061
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1291592
CY2023Q2 eyen Equipment Deposits
EquipmentDeposits
257950
CY2022Q4 eyen Equipment Deposits
EquipmentDeposits
726326
CY2023Q2 us-gaap Assets
Assets
29346899
CY2022Q4 us-gaap Assets
Assets
31036413
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1312749
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1428283
CY2023Q2 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
1013118
CY2022Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
1747191
CY2023Q2 eyen Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
363431
CY2022Q4 eyen Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
503076
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
427749
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
484882
CY2023Q2 eyen Notes Payable Unamortized Discount Current
NotesPayableUnamortizedDiscountCurrent
91621
CY2022Q4 eyen Notes Payable Unamortized Discount Current
NotesPayableUnamortizedDiscountCurrent
33885
CY2023Q2 us-gaap Short Term Bank Loans And Notes Payable
ShortTermBankLoansAndNotesPayable
947163
CY2022Q4 us-gaap Short Term Bank Loans And Notes Payable
ShortTermBankLoansAndNotesPayable
174448
CY2023Q2 eyen Convertible Notes Payable Unamortized Discount Current
ConvertibleNotesPayableUnamortizedDiscountCurrent
0
CY2022Q4 eyen Convertible Notes Payable Unamortized Discount Current
ConvertibleNotesPayableUnamortizedDiscountCurrent
33885
CY2022Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
174448
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
4064210
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4512328
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1584218
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
907644
CY2023Q2 eyen Notes Payable Unamortized Discount Noncurrent
NotesPayableUnamortizedDiscountNoncurrent
1120372
CY2022Q4 eyen Notes Payable Unamortized Discount Noncurrent
NotesPayableUnamortizedDiscountNoncurrent
813229
CY2023Q2 us-gaap Other Long Term Notes Payable
OtherLongTermNotesPayable
8683794
CY2022Q4 us-gaap Other Long Term Notes Payable
OtherLongTermNotesPayable
4190938
CY2023Q2 eyen Convertible Notes Payable Unamortized Discount Noncurrent
ConvertibleNotesPayableUnamortizedDiscountNoncurrent
507270
CY2022Q4 eyen Convertible Notes Payable Unamortized Discount Noncurrent
ConvertibleNotesPayableUnamortizedDiscountNoncurrent
813229
CY2023Q2 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
4492730
CY2022Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
4190938
CY2022Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
2416
CY2023Q2 us-gaap Liabilities
Liabilities
18824952
CY2022Q4 us-gaap Liabilities
Liabilities
13801848
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
6000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
6000000
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
90000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
90000000
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
38169398
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36668980
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
3817
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
3667
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
140703819
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
135461361
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-130185689
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-118230463
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
10521947
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
17234565
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
29346899
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
31036413
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2811061
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3586866
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5333011
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7299450
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3149809
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3534590
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6086695
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7009555
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
5960870
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
7121456
us-gaap Operating Expenses
OperatingExpenses
11419706
us-gaap Operating Expenses
OperatingExpenses
14309005
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5960870
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-7121456
us-gaap Operating Income Loss
OperatingIncomeLoss
-11419706
us-gaap Operating Income Loss
OperatingIncomeLoss
-14309005
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
119450
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
33376
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
190443
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
26303
CY2023Q2 us-gaap Interest Expense
InterestExpense
558003
CY2022Q2 us-gaap Interest Expense
InterestExpense
153436
us-gaap Interest Expense
InterestExpense
1012006
us-gaap Interest Expense
InterestExpense
298673
CY2023Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
183563
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
286043
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
2610
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-6215860
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-7239100
us-gaap Net Income Loss
NetIncomeLoss
-11955226
us-gaap Net Income Loss
NetIncomeLoss
-14578765
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.16
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.22
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.22
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.32
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.32
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.46
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.46
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38093826
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38093826
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33644867
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33644867
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37753694
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37753694
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
31836582
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
31836582
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
17234565
CY2023Q1 eyen Stock Issued At Market Offering During Period Value New Issues
StockIssuedAtMarketOfferingDuringPeriodValueNewIssues
3499592
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
819064
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5739366
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
15813855
CY2023Q2 eyen Stock Issued At Market Offering During Period Value New Issues
StockIssuedAtMarketOfferingDuringPeriodValueNewIssues
403120
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
27200
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
493632
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-6215860
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
10521947
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
20466615
CY2022Q1 eyen Stock Issued During Period Value New Issues Two
StockIssuedDuringPeriodValueNewIssuesTwo
14897908
CY2022Q1 eyen Stock Issued At Market Offering During Period Value New Issues
StockIssuedAtMarketOfferingDuringPeriodValueNewIssues
860365
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
908987
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-7339665
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
29794210
CY2022Q2 eyen Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
18701
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1036926
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-7239100
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
23610737
us-gaap Net Income Loss
NetIncomeLoss
-11955226
us-gaap Net Income Loss
NetIncomeLoss
-14578765
us-gaap Share Based Compensation
ShareBasedCompensation
1312696
us-gaap Share Based Compensation
ShareBasedCompensation
1945913
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
187267
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
145901
eyen Amortization Of Debt Discount
AmortizationOfDebtDiscount
313446
eyen Amortization Of Debt Discount
AmortizationOfDebtDiscount
52431
us-gaap Noncash Contribution Expense
NoncashContributionExpense
280968
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1514
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
461761
eyen Increase Decrease In License Fee And Expense Reimbursements Receivables
IncreaseDecreaseInLicenseFeeAndExpenseReimbursementsReceivables
-754780
eyen Increase Decrease In License Fee And Expense Reimbursements Receivables
IncreaseDecreaseInLicenseFeeAndExpenseReimbursementsReceivables
-1095831
eyen Increase Decrease In Deferred Clinical Supply Costs
IncreaseDecreaseInDeferredClinicalSupplyCosts
1293395
eyen Increase Decrease In Deferred Clinical Supply Costs
IncreaseDecreaseInDeferredClinicalSupplyCosts
1538380
us-gaap Increase Decrease In Security Deposits
IncreaseDecreaseInSecurityDeposits
1750
us-gaap Increase Decrease In Security Deposits
IncreaseDecreaseInSecurityDeposits
-68868
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-115534
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1072690
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-734073
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-529534
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-139645
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-21417
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-284996
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
2356
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11673476
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12883603
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2122197
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
281342
eyen Vendor Deposits For Property Plant And Equipment
VendorDepositsForPropertyPlantAndEquipment
118298
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2122197
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-399640
eyen Proceeds From Sale Of Common Stock And Warrants In Registered Direct Offering
ProceedsFromSaleOfCommonStockAndWarrantsInRegisteredDirectOffering
14981299
eyen Payments For Repurchase Of Public Offering
PaymentsForRepurchaseOfPublicOffering
83391
eyen Proceeds From Issuance Of Common Stock At Market Offering
ProceedsFromIssuanceOfCommonStockAtMarketOffering
4023414
eyen Proceeds From Issuance Of Common Stock At Market Offering
ProceedsFromIssuanceOfCommonStockAtMarketOffering
886974
eyen Payments Of Stock Issuance Costs At Market Offering
PaymentsOfStockIssuanceCostsAtMarketOffering
120702
eyen Payments Of Stock Issuance Costs At Market Offering
PaymentsOfStockIssuanceCostsAtMarketOffering
26609
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
27200
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
18701
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
5000000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
125982
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
403689
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
448999
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8400241
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15327975
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-5395432
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2044732
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
22863520
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
27336850
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17468088
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
29381582
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17468088
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21506582
CY2022Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
7875000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17468088
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
29381582
us-gaap Interest Paid Capitalized
InterestPaidCapitalized
699116
us-gaap Interest Paid Capitalized
InterestPaidCapitalized
199367
eyen Purchase Of Insurance Premium Financed By Short Term Note Payable
PurchaseOfInsurancePremiumFinancedByShortTermNotePayable
609140
eyen Purchase Of Insurance Premium Financed By Short Term Note Payable
PurchaseOfInsurancePremiumFinancedByShortTermNotePayable
675331
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
904437
us-gaap Escrow Deposit Disbursements Related To Property Acquisition1
EscrowDepositDisbursementsRelatedToPropertyAcquisition1
468376
eyen Original Issue Discount On Notes Payable
OriginalIssueDiscountOnNotesPayable
212500
eyen Cashless Exercise Of Stock Options
CashlessExerciseOfStockOptions
2
eyen Issuance Of Common Stock Related To Vested Restricted Stock Units
IssuanceOfCommonStockRelatedToVestedRestrictedStockUnits
4
eyen Issuance Of Common Stock Related To Vested Restricted Stock Units
IssuanceOfCommonStockRelatedToVestedRestrictedStockUnits
7
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17500000
us-gaap Net Income Loss
NetIncomeLoss
-12000000.0
us-gaap Net Income Loss
NetIncomeLoss
-14600000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11700000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12900000
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reclassifications</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Certain prior period amounts presented on the Company’s financial statements have been reclassified in order to conform to current period presentation. These reclassifications have no effect on previously reported results of operations or loss per share.</p>
CY2023Q2 us-gaap Treasury Stock Value
TreasuryStockValue
4493766
CY2023Q2 us-gaap Cash Uninsured Amount
CashUninsuredAmount
12474323
CY2022Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
22613520
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6215860
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7239100
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11955226
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14578765
CY2023Q2 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
38064215
CY2022Q2 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
31669431
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
37724083
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
31089811
CY2022Q2 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
1870130
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
671594
CY2023Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
29611
CY2022Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
105306
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
29611
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
75177
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38093826
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33644867
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37753694
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
31836582
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.22
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.32
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.46
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13686875
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11125705
CY2023Q2 eyen Payroll Taxes Receivable
PayrollTaxesReceivable
645566
CY2022Q4 eyen Payroll Taxes Receivable
PayrollTaxesReceivable
660891
CY2023Q2 us-gaap Prepaid Insurance
PrepaidInsurance
600607
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
201082
CY2023Q2 eyen Prepaid General And Administrative Expenses
PrepaidGeneralAndAdministrativeExpenses
310701
CY2022Q4 eyen Prepaid General And Administrative Expenses
PrepaidGeneralAndAdministrativeExpenses
87982
CY2023Q2 eyen Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
83192
CY2022Q4 eyen Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
2521
CY2023Q2 eyen Prepaid Patent Expense
PrepaidPatentExpense
73157
CY2022Q4 eyen Prepaid Patent Expense
PrepaidPatentExpense
38796
CY2023Q2 eyen Prepaid Conference Expenses
PrepaidConferenceExpenses
69400
CY2022Q4 eyen Prepaid Conference Expenses
PrepaidConferenceExpenses
97743
CY2023Q2 eyen Prepaid Rent And Security Deposit
PrepaidRentAndSecurityDeposit
18750
CY2022Q4 eyen Prepaid Rent And Security Deposit
PrepaidRentAndSecurityDeposit
74959
CY2023Q2 us-gaap Other Assets
OtherAssets
0
CY2022Q4 us-gaap Other Assets
OtherAssets
26745
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1801373
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1190719
CY2023Q2 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
695450
CY2022Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1447643
CY2023Q2 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
317668
CY2022Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
299548
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1013118
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1747191
CY2023Q2 eyen Accrued Consulting And Professional Services Current
AccruedConsultingAndProfessionalServicesCurrent
142915
CY2022Q4 eyen Accrued Consulting And Professional Services Current
AccruedConsultingAndProfessionalServicesCurrent
320000
CY2023Q2 eyen Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
117983
CY2022Q4 eyen Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
35524
CY2023Q2 eyen Accrued Leasehold Improvements Current
AccruedLeaseholdImprovementsCurrent
0
CY2022Q4 eyen Accrued Leasehold Improvements Current
AccruedLeaseholdImprovementsCurrent
92528
CY2023Q2 eyen Credit Card Payable
CreditCardPayable
58549
CY2022Q4 eyen Credit Card Payable
CreditCardPayable
50639
CY2023Q2 eyen Accrued Franchise Tax
AccruedFranchiseTax
26201
CY2022Q4 eyen Accrued Franchise Tax
AccruedFranchiseTax
0
CY2023Q2 eyen Accrued Travel And Entertainment Expenses Current
AccruedTravelAndEntertainmentExpensesCurrent
13784
CY2022Q4 eyen Accrued Travel And Entertainment Expenses Current
AccruedTravelAndEntertainmentExpensesCurrent
0
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3999
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
4385
CY2023Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
363431
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
503076
CY2023Q2 us-gaap Notes Payable Current
NotesPayableCurrent
1038784
CY2023Q2 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
91621
CY2023Q2 eyen Notes Payable Current Net Of Debt Discount Current Current Portion
NotesPayableCurrentNetOfDebtDiscountCurrentCurrentPortion
947163
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
416666
CY2022Q4 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
67770
CY2022Q4 eyen Notes Payable Current Net Of Debt Discount Current Current Portion
NotesPayableCurrentNetOfDebtDiscountCurrentCurrentPortion
348896
CY2023Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
14804166
CY2023Q2 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
1627642
CY2023Q2 eyen Notes Payable Non Current Net Of Debt Discount Non Current Non Current Portion
NotesPayableNonCurrentNetOfDebtDiscountNonCurrentNonCurrentPortion
13176524
CY2022Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
10008334
CY2022Q4 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
1626458
CY2022Q4 eyen Notes Payable Non Current Net Of Debt Discount Non Current Non Current Portion
NotesPayableNonCurrentNetOfDebtDiscountNonCurrentNonCurrentPortion
8381876
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
403689
CY2023Q2 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
126000
us-gaap Operating Lease Payments
OperatingLeasePayments
284996
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
904437
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y6M
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.100
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
445025
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
660923
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
675400
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
560996
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
214619
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2556963
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
544996
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
2011967
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
427749
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1584218
eyen Proceeds From Issuance Of Common Stock Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
3900000
us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
1421936
CY2023Q2 us-gaap Share Based Compensation
ShareBasedCompensation
493632
CY2022Q2 us-gaap Share Based Compensation
ShareBasedCompensation
1036926
us-gaap Share Based Compensation
ShareBasedCompensation
1312696
us-gaap Share Based Compensation
ShareBasedCompensation
1945913
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
172800
CY2022Q4 eyen Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Non Vested Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice
1.80
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
86205
eyen Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice
2.32
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
150578
eyen Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Vested In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedInPeriodWeightedAverageExercisePrice
1.80
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
22222
eyen Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Forfeited In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsForfeitedInPeriodWeightedAverageExercisePrice
1.80
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
86205
CY2023Q2 eyen Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Non Vested Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice
2.32
eyen Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested Rs Us Undelivered Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedRSUsUndeliveredNumber
29611
eyen Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Vested Rs Us Undelivered Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedRSUsUndeliveredWeightedAverageExercisePrice
3.68
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0279
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0279
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.88
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.88
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2023Q2 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
5185078
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P6Y2M12D
CY2023Q2 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
3582370
CY2023Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
2868023
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y8M12D
CY2019Q2 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
1
CY2019Q2 us-gaap Defined Contribution Plan Employers Matching Contribution Annual Vesting Percentage
DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage
0.04
CY2023Q2 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Amount
DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
46196
CY2022Q2 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Amount
DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
47883
us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Amount
DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
125164
us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Amount
DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
133982
ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001410578-23-001760-index-headers.html Edgar Link pending
0001410578-23-001760-index.html Edgar Link pending
0001410578-23-001760.txt Edgar Link pending
0001410578-23-001760-xbrl.zip Edgar Link pending
eyen-20230630.xsd Edgar Link pending
eyen-20230630x10q.htm Edgar Link pending
eyen-20230630xex31d1.htm Edgar Link pending
eyen-20230630xex31d2.htm Edgar Link pending
eyen-20230630xex32d1.htm Edgar Link pending
eyen-20230630xex32d2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
eyen-20230630_def.xml Edgar Link unprocessable
eyen-20230630_lab.xml Edgar Link unprocessable
eyen-20230630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
eyen-20230630x10q_htm.xml Edgar Link completed
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
eyen-20230630_cal.xml Edgar Link unprocessable